ARCHIVES

Randomized Trials Discovered Roles For Newly Approved Nexavar and Sutent.

This article is from The Cancer Letter archive.

Vol. 32 No. 07 | February 24, 2006

Download PDF Visit The Full Archive

Related Articles

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

June 16, 1999

Hormonal Therapy Improves Prostate Cancer Survival

August 27, 2004

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

Reimbursement Of Some Anticancer Drugs Expected To Drop Sharply Under HHS Policy.

June 30, 2000

Vanderbilt Wins NCI Core Grant Renewal with 12.7 Percent Funding increase

December 3, 2010

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002